Evotec is a German company that serves as a research and development partner for many pharmaceutical and biotech companies. Its share price reflects the scale of its R&D in the industry, as Evotec provides its platforms and expertise for the discovery of new drugs.
Evotec is a German company that serves as a research and development partner for many pharmaceutical and biotech companies. We classify it as part of the Pharmaceutical Testing sector, and the chart below reflects the dynamics of the entire R&D outsourcing industry.
Evotec is a German biotechnology company that provides drug discovery and development services to the pharmaceutical industry. Its role in R&D makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Evotec compares to it.
The volatility of Evotec, a contract research organization, reflects the state of the biopharmaceutical industry. Change_co measures sensitivity to R&D spending and partnership news. This metric forms the basis for analysis of the pharmaceutical services sector on System.GURU.Markets.
Evotec SE is a contract research organization (CRO). This chart shows the average daily volatility of the healthcare sector. Compared to EVO, whose revenue depends on pharmaceutical companies' R&D budgets, it serves as a barometer of innovation in the pharmaceutical industry.
Evotec is a German biotechnology company providing drug discovery and development services to the pharmaceutical industry. Its business serves as a barometer of activity in the global pharmaceutical industry. The chart below shows general market fluctuations, which can be used to assess Evotec's stability.
Evotec is a German company and a leader in pharmaceutical services, from research to production. Its annual growth rate serves as a benchmark for R&D investment in the biotech industry.
Evotec SE is a leading German company providing drug development services to the pharmaceutical and biotech industries. Its scientific expertise and wide range of services make it a key R&D partner. The chart shows how its unique model, combining services and in-house development, influences its growth.
Evotec, a drug development company, is a gold mine in the biotech world. Demand for its services is stable, as pharmaceutical companies spend on R&D throughout the economic cycle. Its share price (ADR) often shows smoother and more predictable growth than the overall market.
The market capitalization of Evotec, a contract research organization (CRO), depends on R&D cycles in the pharmaceutical industry. The monthly fluctuations on the chart reflect demand for its drug development services from pharmaceutical and biotech companies, which ensures stable growth.
Evotec SE is a leading global research and development company, partnering with pharmaceutical and biotech companies to accelerate the discovery and development of new drugs. Its sector dynamics, shown in the graph, reflect the volume of R&D. Against this backdrop, one can appreciate how Evotec's unique business model, combining services and proprietary developments, creates value.
Evotec is a German company providing drug research and development services to pharmaceutical and biotech companies worldwide. Its business relies on global R&D spending. A chart of the overall market performance helps understand how Evotec shares correlate with overall sentiment in the healthcare sector, which is considered relatively defensive.
Evotec, a German biotech company providing drug development services to the pharmaceutical industry, whose weekly stock price reflects R&D activity in the sector. News of partnerships with major pharmaceutical companies and achievement of key research milestones shape short-term trends.
Evotec, as a service company for the pharmaceutical industry, is a barometer for the sector. The chart compares its performance with the industry, demonstrating how much its results are influenced by industry-wide trends in R&D spending, which is its primary source of revenue.
Evotec is a German company providing drug development services to pharmaceutical and biotech companies. Its business is stable. The chart will show whether Evotec shares act as a safe haven, demonstrating less volatility than the market due to consistent R&D spending in its industry.
Evotec SE's market capitalization is a financial map of partnerships in the world of drug development. This German company's chart reflects not so much its own drugs as its role as a key research partner for the entire pharmaceutical industry. Its dynamics are a barometer of R&D outsourcing and activity in the search for new molecules.
Evotec is a global research and development company providing services to the pharmaceutical and biotech industries. Its market share reflects its key role as a partner for many drug developers. The chart below shows Evotec's position in the ecosystem that accelerates drug discovery.
Evotec is a leading research and development company that partners with pharmaceutical and biotech companies. The chart below shows the overall market capitalization of the entire biotech sector. Its growth reflects R&D outsourcing and the need for innovative drug discovery platforms.
Evotec is a German biotech company that partners with pharmaceutical giants, assisting them in drug research and development. Its market capitalization chart tells the story of scientific collaboration, demonstrating how R&D outsourcing is becoming an increasingly important part of the pharmaceutical industry.
Evotec, a research company, derives its book value from its laboratories and cutting-edge scientific equipment worldwide. The chart below shows how the company is building a platform for drug discovery. Growth in this chart reflects investments in the material base for R&D partnerships with pharmaceutical giants.
Evotec is a research and development partner for the pharmaceutical industry. Its strength lies in its network of advanced laboratories where experiments are conducted for other companies. The asset share chart demonstrates the scale of this unique physical infrastructure, which acts as an "outsourced scientific factory."
Evotec is a partner for pharmaceutical companies, providing drug research and development services. Its value lies in its scientific platforms, data, and laboratories equipped with sophisticated equipment. The book value chart shows how investments in research-intensive assets shape its business model.
Evotec's book value is a global platform for pharmaceutical research. The company's assets include dozens of laboratories around the world, equipped with the latest drug development equipment, from robotics to cell analyzers. The chart shows the physical scale of this scientific infrastructure, accessible to the entire biopharmaceutical industry.
Evotec is a contract research organization that helps pharmaceutical companies develop drugs. Its value lies not so much in its laboratories (balance sheet), but in its scientific expertise, partnerships, and participation in future royalties. Its market capitalization reflects its unique role in the drug discovery ecosystem.
Evotec SE is a German biotech company that collaborates with pharmaceutical giants on research and development. Its value lies in its scientific platform and partnerships. The chart shows the premium the market pays for its scientific expertise and project portfolio over and above the cost of its laboratories and equipment.
Evotec is a global drug research and development company. Its core assets are scientific expertise, technology platforms, and partnerships with pharmaceutical giants. The chart shows the market premium placed on intellectual capital and the company's role in the innovation ecosystem, valuing it significantly above its tangible assets.
Evotec, a biotech research and development services company, is using debt to expand its platforms and strategic partnerships. This chart reflects investments in cutting-edge laboratory equipment and technologies, as well as potential acquisitions to strengthen its capabilities.
Evotec is a global company providing drug research and development services to the pharmaceutical industry. In this knowledge-intensive service business, debt can be used to expand laboratory capacity and acquire new technologies. The chart shows how Evotec's financial strategy supports its position as a partner for big pharma.
Evotec SE partners with pharmaceutical companies, providing research and development services for pharmaceuticals. This business requires ongoing investment in scientific platforms and technologies. This chart shows how the company funds its laboratories and innovations, allowing one to evaluate its financial strategy in its quest to remain at the forefront of science.
Evotec is a German biotech company that partners with pharmaceutical companies in drug research and development. Its business model is less risky than that of traditional biotech companies. The chart shows the overall debt burden in the industry, allowing one to assess how Evotec finances its research platforms and partnerships.
Evotec, a pharmaceutical company's R&D partner, is dependent on industry research budgets. This chart shows the overall market debt burden. It helps assess how general economic conditions and capital availability for large pharmaceutical companies influence their willingness to outsource research, which directly impacts Evotec's business.
Evotec SE partners with pharmaceutical and biotech companies, providing research and development services for new drugs. This chart shows how much investors value its integrated platform. Its growth reflects confidence that R&D outsourcing will remain a key trend, providing Evotec with a steady stream of orders.
Evotec SE operates in the outsourced R&D services sector for pharmaceutical companies. This chart shows the average P/E for this industry. A company's P/E is higher than the industry average, indicating that investors consider its scientific platform and partnerships more valuable and promising than those of other contract research organizations.
Evotec SE is a German biotech company that collaborates with pharmaceutical giants on the research and development of new drugs. Its business model is based on partnerships and milestone payments. This chart shows the company's overall risk appetite. It helps understand whether Evotec is perceived as a stable service partner or a risky biotech company dependent on the success of its developments.
Evotec SE is a global company providing drug research and development partnerships for the pharmaceutical and biotechnology industries. The chart shows the estimated outsourcing prospects for R&D. Future profits depend on new alliances, achieving key milestones in partnership programs, and expanding the company's technology platform.
%20P%2FE%20Evotec%20SE&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Evotec-SE "Chart of the company's future (projected) P/E Evotec SE")
Evotec SE is a German biotech company that partners with major pharmaceutical companies in the research and development of new drugs. This chart compares Evotec's profitability expectations with those of its industry peers. It demonstrates the market's confidence in its scientific platform and ability to generate stable income from partnerships and royalties.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Evotec SE is a global company providing drug research and development services to the pharmaceutical and biotechnology industries. Its business depends on R&D investment in the healthcare sector. This chart, reflecting overall market optimism, demonstrates the willingness of large companies and investors to invest in long-term scientific projects, securing orders for Evotec.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Evotec SE is a global partner for pharmaceutical and biotech companies, providing research and development services for pharmaceutical companies. The company's revenue depends on the number and scale of its partnership programs, as well as milestone payments for scientific achievements. This chart shows how R&D investments in the pharmaceutical industry translate into revenue for the service company.
Evotec SE is a global partner for pharmaceutical and biotech companies, providing drug discovery and development services. The total revenue in this service segment, reflected in the graph, depends on R&D budgets in the pharmaceutical industry. Evotec's success in building long-term alliances and achieving scientific results drives growth for the entire ecosystem.
Evotec is a global partner for pharmaceutical and biotech companies, providing drug research and development services. The company benefits from outsourcing R&D as pharma giants strive to improve efficiency. Its growth reflects the health of the entire biopharmaceutical ecosystem, which continues to actively invest in innovation.
Evotec SE is a German biotech company that collaborates with pharmaceutical giants on the research and development of new drugs. This chart shows analysts' expectations for future profits, which depend on new partnerships, project milestones, and the overall health of the pharmaceutical R&D sector.
%20profit%20of%20the%20company%20Evotec%20SE&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Evotec-SE "Graph of future (projected) profit of the company Evotec SE")
Evotec SE is a global company providing partnership solutions in drug research and development. This chart shows future revenue projections for the entire pharmaceutical research segment. It allows one to assess how Evotec's business model, based on collaboration with pharmaceutical giants, fits into the overall expectations of R&D productivity in the industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
Evotec SE is a global company providing research and development services for the pharmaceutical industry. Its revenues depend on the R&D budgets of major pharmaceutical companies. This graph, showing corporate profit forecasts, impacts Evotec, as pharmaceutical giants invest more actively in outsourced research during periods of growth and confidence.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Evotec SE partners with pharmaceutical and biotech companies, providing research and development services for new drugs. This chart, comparing market capitalization to revenue, reflects the company's unique business model. It demonstrates the premium investors pay for its scientific expertise and role in the innovative drug discovery ecosystem.
Evotec SE is a leading global company that partners with pharmaceutical and biotech companies across all stages of drug discovery and development. It provides comprehensive scientific services and platforms. This chart reflects how the market values revenue in the CRO sector, demonstrating the level of trust in Evotec's scientific expertise and partnership model.
Evotec SE is a global company providing drug research and development services to the pharmaceutical and biotechnology industries. The company's business model is based on partnerships and joint development. This chart helps understand how investors value this biotechnology services company compared to average market revenue valuations.
Evotec SE is a global company providing drug research and development services to the pharmaceutical and biotechnology industries. This chart illustrates the company's investor valuation based on expected future revenue from partnerships and contract research. It reflects the company's belief in R&D outsourcing and the success of joint projects with partners.
%20P%2FS%20Evotec%20SE&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Evotec-SE "The graph of the company's future (projected) P/S Evotec SE")
Evotec SE is a global company providing partnership solutions in drug research and development for the pharmaceutical and biotech industries. The data in the chart compares the company's estimated future sales with those of its competitors. A leading estimate may indicate confidence in its unique platform and increased R&D outsourcing, while a trailing estimate may indicate risks in partnership projects.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Evotec is a global biotech company that partners with pharmaceutical companies to accelerate the development of new drugs. Its business model is based on partnerships and milestone payments. This market expectations chart reflects the overall investor confidence in pharmaceutical innovation and increased investment in research and development.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
Evotec's revenue dynamics reflect activity in the global pharmaceutical industry. The company doesn't sell its own drugs, but rather serves as a research and development partner for other pharmaceutical companies. Growing sales translate into an increasing number of contracts, milestone payments for successful research stages, and strong demand for its scientific platforms.
Evotec SE is a global R&D services company for the pharmaceutical and biotech industries. It helps partners accelerate the development of new drugs. This chart shows the total revenue of the entire contract research organization (CRO) market, illustrating the scale of R&D outsourcing, where Evotec is a key player.
Evotec SE is a global company providing drug research and development services to the pharmaceutical and biotechnology industries. Its revenue depends on the volume of R&D investments made by its partners. This chart, illustrating the overall state of the economy, is an indicator of capital availability and the willingness of large companies to invest in R&D outsourcing.
Evotec SE is an international company that partners with pharmaceutical and biotech companies, providing drug discovery and development services. Its revenue is driven by industry R&D budgets. This chart shows analyst forecasts for innovative drug development activity and demand for outsourced research.
%20sales%20of%20the%20company%20Evotec%20SE&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Evotec-SE "Schedule of future (projected) sales of the company Evotec SE")
Evotec SE is a global company providing partnership solutions in drug research and development. This chart details revenue forecasts for two main segments: EVT Execute (services) and EVT Innovate (co-development). This provides insight into which part of the business model, according to analysts, will be the company's primary growth driver.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
The overall investment climate in the pharmaceutical industry, reflected in this chart, is critical for Evotec. This research company collaborates with pharmaceutical giants on the development of new drugs. Its revenue depends on R&D budgets, which partners are more willing to increase during periods of economic growth and confidence in the future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Evotec SE partners with pharmaceutical and biotech companies, providing research and development services for new drugs. This chart shows the profitability of its hybrid business model. Revenue is generated through service fees, milestone payments for scientific achievements, and potential royalties from future drug sales.
Evotec is a German company that collaborates with pharmaceutical and biotech companies at all stages of drug development, from research to manufacturing. Its profitability depends on the number and success of its partnership programs. This chart shows the average profitability in the pharmaceutical industry. It allows you to assess the effectiveness of Evotec's unique business model as an R&D partner.
Evotec SE is a German company providing research and development services to the pharmaceutical and biotech industries. Its business depends on the R&D budgets of its clients. This chart shows the overall financial health of large pharmaceutical companies. It helps understand whether they have the resources to outsource research, which directly generates business for Evotec.
Evotec SE is a global research and development company providing services to the pharmaceutical and biotech industries. This chart shows the size of its vast scientific team, working in partnership with other companies to discover new drugs. This growth clearly demonstrates the expansion of its partnerships and the company's strengthening position as a key R&D hub.
Evotec partners with pharmaceutical and biotech companies, offering comprehensive drug development services. Its core assets are its scientists and laboratory technicians. This chart shows Evotec's share of all researchers in the contract research organization (CRO) sector. This reflects the scale of its scientific platform and the trust it enjoys from its clients.
Evotec SE is a global partner for pharmaceutical and biotech companies, providing drug research and development services. The chart reflects employment in the pharmaceutical research and testing sector. The growing number of scientists and technicians in this field indicates an increase in R&D outsourcing, a key growth driver for Evotec's service-based business model.
Evotec SE partners with pharmaceutical and biotech companies, providing research and development services for pharmaceuticals. Their growth depends on the volume of R&D investment in the industry. This chart shows the overall economics, but for Evotec, the key drivers are the influx of venture capital and the budgets of large pharmaceutical companies for research outsourcing.
Evotec is a global company providing drug discovery and development services to the pharmaceutical industry. It's a knowledge-intensive business, requiring a large staff of scientists and lab technicians. This chart shows how the market values their scientific platform, the value of which is created by the collective intelligence of thousands of researchers.
%20of%20the%20company%20Evotec%20SE%20(EVO)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Evotec-SE-EVO "Chart of market capitalization per employee (in thousands of dollars) of the company Evotec SE (EVO)")
Evotec SE is a German company serving as an R&D partner for the pharmaceutical and biotechnology industries. They assist other companies in drug discovery and development. Their business is based on scientific expertise and cutting-edge technologies. This indicator helps assess the market value of their R&D services per scientist.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Evotec partners with pharmaceutical and biotech companies, providing drug research and development services. It's a science-intensive business where value is created by the experience and efficiency of its scientists. This chart shows how the market values the company's intellectual capital and operating model, where every researcher contributes to the development of future drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Evotec is an "R&D factory" for the pharmaceutical industry. They operate as a contract research organization (CRO), providing their research platforms and scientists to develop drugs for other companies. This chart shows how profitably they "sell" their researchers' time and expertise in managing complex scientific projects.
%20Chart%20Evotec%20SE%20(EVO)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Evotec-SE-EVO "Company Profit Per Employee (in thousands of dollars) Chart Evotec SE (EVO)")
Evotec is a "CRO" (Contract Research Organization). It's an "R&D outsourcer" that "conducts" "research" (drug discovery) under contract for pharma giants. This graph shows the benchmark for "Pharm Tests." This "B2B service" has a moderate benchmark. It's a "people-based business," where profit per employee (scientist) is generated by billable hours.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Evotec SE is a German company that serves as a research and development partner for the entire pharmaceutical industry. They don't create their own drugs, but rather provide other companies with a platform (laboratories, scientists, and data) for their discovery. This chart helps us understand how cost-effective the "science as a service" model, which requires a large staff of qualified researchers, is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Evotec SE is a global company providing drug research and development services to the pharmaceutical industry. Revenue per employee is an indicator of the productivity of its highly qualified scientists. The chart reflects the number and scale of partnership programs, demonstrating how scientific expertise translates into stable income.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Evotec-SE-EVO "Sales chart per company employee Evotec SE (EVO)")
Evotec is a research and development partner for the biotech and pharmaceutical industries. They don't sell finished drugs, but rather provide their scientific platforms and expertise on a contract basis. This chart shows how effectively their army of scientists monetizes their services by working on client projects. It's an indicator of the demand for their R&D platforms.
Evotec (EVO) is a German biotech company that serves as a research and development partner (CRO/CDMO) for the entire pharmaceutical industry. They help other companies discover and manufacture drugs. It's a science-as-a-service business. This chart shows how productive their laboratories are. It reflects how revenue from partnership projects compares to their large staff of highly qualified scientists.
Evotec SE is a German company that serves as an R&D partner for the pharmaceutical and biotech industries. They help discover and develop new drugs using their advanced technology platforms. This chart shows bearish bets. Skeptics may fear that slowing funding in the biotech sector will lead to cuts in R&D budgets for Evotec's clients, reducing their revenue from collaboration.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Evotec-SE-EVO "Short Shares Chart for the Company Evotec SE (EVO)")
Evotec (EVO) is a German company that serves as an R&D partner for pharmaceutical and biotech companies. They assist in the discovery and development of new drugs. This chart reflects bets against the pharmaceutical research sector. If investors are short this sector, they likely expect a reduction in venture capital funding for biotech companies, which will force them to cut their research outsourcing budgets.
Evotec (EVO) is an R&D partner for pharmaceutical companies (CROs). This Short_All chart shows "risk aversion." This pessimism is drying up venture capital funding for biotechs (EVO's clients). As a result, they have no money left for outsourcing research—Evotec's core business.
Evotec is a German company that serves as an R&D partner for large pharmaceutical companies, assisting them in drug discovery and development. It's the "pick and shovel" of biotech. This chart measures how the market values R&D outsourcing. It shows when the stock is overbought on expectations of pharmaceutical budget growth or oversold on fears of a downturn.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Evotec-SE-EVO "RSI 14 indicator chart for the company's stock Evotec SE (EVO)")
Evotec is a German company that serves as a research partner (CRO) for the pharmaceutical and biotech industries. They provide services for the discovery and development of new drugs. This chart reflects the overall state of the CRO sector and helps understand whether the entire segment is oversold amid changes in biotech R&D budgets.
Evotec (EVO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Evotec SE is a German company providing research and development (R&D) services to pharmaceutical and biotech companies. This chart shows the average analyst forecast. Their targets are based on the growth of partnerships, the order backlog, and progress on internal and joint R&D projects.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EVO-Evotec-SE "A chart showing analyst consensus forecasts for the expected stock price. EVO (Evotec SE)")
Evotec (EVO) is a German contract research organization (CRO) that serves as an R&D partner for biotech companies, discovering and developing new drugs for them. This chart shows their model's valuation. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their R&D outsourcing platform.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EVO-Evotec-SE "A chart showing the difference between the consensus forecast and the actual stock price. EVO (Evotec SE)")
Evotec is a German company that provides drug discovery and development services to pharmaceutical giants (CRO model) and also develops its own projects. This chart shows analysts' general expectations for the pharma testing sector. It reflects whether experts believe R&D outsourcing will grow in the pharmaceutical industry.
Evotec (EVO) is an outsourced laboratory. They are a German CRO, an R&D (drug discovery) partner for big pharma and biotech. This graph, reflecting expert expectations, influences their clients. If the market is pessimistic and risk appetite declines, biotechs cut their early R&D budgets (Evotec's work).
Evotec is a premium German R&D outsourcer. It's a drug discovery and development powerhouse that collaborates with big pharma and biotech companies across all stages, from idea to clinical stage. This chart is a barometer of R&D outsourcing. It likely aggregates their order book, partnership growth, and their ability to collect mileage payments from partners.
Evotec (EVO) is a German R&D giant; the company operates as a CRO, providing a full range of early development services (from concept to clinical stage) for the entire pharmaceutical industry. This aggregate metric evaluates companies. The graph shows the average value for the segment. This benchmark: how does this large-scale service (CRO) model (EVO) differentiate it from the average pharmaceutical company?
Evotec is a German company providing drug discovery and development services (CRO/CDMO) to the pharmaceutical industry. This chart, reflecting the market average, provides context. It helps assess how this R&D partner, dependent on biotech and pharma budgets, compares to the overall economic trends affecting the healthcare sector.
